Segal appointed CHPA director of federal affairs
WASHINGTON Allen Segal joined the Consumer Healthcare Products Association’s government affairs department Feb. 20 as the director of federal affairs, the association announced Friday.
Segal comes to the association from the American Cancer Society, where he served as associate director of congressional relations. Prior to that, he held federal legislative and political liaison positions with the National Association of Home Builders, and was a special assistant for legislation at the National Association of Letter Carriers.
In his new role at CHPA, Segal will be responsible for directing the association’s federal government affairs efforts.
Products can’t claim effectiveness against diseases, FDA says
ROCKVILLE, Md. The Food and Drug Administration on Friday announced that Brownwood Acres Foods, Cherry Capital Services—doing business as Flavonoid Sciences—and two of their top executives have signed a consent decree that effectively prohibits the companies and their executives from manufacturing and distributing any products with claims in the label or labeling to cure, treat, mitigate or prevent diseases.
The consent decree of permanent injunction is a result of the companies and their executives making unapproved drug claims and unauthorized health claims about their products, such as “Chemicals found in Cherries may help fight diabetes.” The companies are prevented from making these claims until the products are approved by the FDA as new drugs, exempt from approval as investigational new drugs, or until the claims on the products’ label and labeling comply with the law, the FDA stated.
“The FDA will not tolerate unsubstantiated health claims that may mislead consumers,” stated Margaret O’K. Glavin, associate commissioner for regulatory affairs. “The FDA will pursue necessary legal action to make sure companies and their executives manufacture and distribute safe, truthfully labeled products to consumers.”
Brownwood Acres Foods and Cherry Capital Services manufacture and distribute various products including juice concentrates, soft fruit gel capsules, fruit bars, dried fruits, liquid glucosamine and salmon oil capsules.
The decree was signed by Judge Paul Maloney on Feb. 19 in the U.S. District Court for the Western District of Michigan.
Study indicates that taking multiple NSAIDs may lead to poorer health
DURHAM, N.C. A new study released recently stated that patients taking more than one nonsteroidal anti-inflammatory drug may have poorer health quality. NSAIDs are available with or without a prescription and that is one of the problems according to the study.
These drugs are widely available, and patients may take both prescription and over-the-counter NSAIDs at the same time, either because they need more pain relief or because they don’t realize the products belong to the same class of drugs, said the study authors, who added that doctors may not know their patients are taking more than one NSAID.
The researchers, led by Stacey Kovac of Durham VA Medical Center and Duke University, found that 26 percent of the patients reported taking at least two NSAIDs (prescription, OTC or both) during the previous month, during the study, which took place from February 2002 until August 2002. These dual users scored lower than others on the physical component of a questionnaire designed to evaluate physical and mental health.
The authors suggest that physicians should keep a complete list of a patient’s medication to help identify which ones are taking more than one NSAID. Also, the researchers conclude their study by saying that, “Adequate pain management may have the potential to reduce dual use, improve patient symptoms, including physical functioning, and reduce patient safety problems.”